Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DUBLIN, Oct. 6, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced that Omar Ishrak has decided not to stand for re-election at the Annual General Meeting in December and will retire as Executive Chairman and Chairman of its Board of Directors effective December 11, 2020....

Omar Ishrak to Retire as Medtronic Executive Chairman and Chairman of the Board; Geoff Martha to Succeed Ishrak as Chairman of the Board, Effective December 11, 2020

We believe that Medtronic stock could offer an upside of roughly 15% from the current levels. MDT stock trades at $102 currently and it is down 9% so far this year as well as from the pre-Covid high of $112 seen in February.

Medtronic Stock Appears Attractive Around $100 Levels

DUBLIN, Oct. 5, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT) announced today that the company will host its biennial Institutional Investor and Analyst Event on Wednesday, October 14, 2020, from 8:00 a.m. to approximately 2:00 p.m. Eastern Daylight Time (7:00 a.m. to approximately 1:00 p....

Medtronic Announces Virtual 2020 Institutional Investor and Analyst Event and Webcast

AbbVie

Boston Scientific

Stryker

Zimmer Biomet Hlds

While technology has been the engine that has driven stock market performance for some time now, increasingly we are seeing a seismic shift to health care among many portfolio managers, and with good reason.

Top Analyst Very Positive on Leading Medical Technology Health Care Stocks for 2021

Atmos Energy

Bank of New York Mellon

Enterprise Products Partners

General Dynamics

Intel

Altria

Prudential Financial

Texas Instruments

This article is part of our monthly series where we highlight five companies that are large cap, relatively safe, dividend paying, and are offering large discounts to their historical norms.

5 Safe And Cheap Dividend Stocks To Invest In (October 2020)

The company has denied all allegations of wrongdoing

Medtronic Under Federal Investigation For Ventilator Shortage

Medtronic plc (NYSE: MDT) is the subject of a probe from the United States Department of Justice over the acquisition of competing ventilator makers, the Wall Street Journal reported Wednesday. What Happened: The investigation stemmed from the shortage of ventilators during the COVID-19 pandemic, according to the Journal.

Medtronic Faces Federal Probe Over Causing Ventilator Shortage During Pandemic: WSJ

Medtronic's (MDT) InterStim system electrically stimulates the sacral nerves.

Medtronic, Axonics Patent War Continues for Sacral Neuromodulation (Revised)

DUBLIN, Sept. 29, 2020 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE:MDT) today announced that its wholly-owned subsidiary Medtronic Global Holdings S.C.A. ("Medtronic Luxco") has closed a registered public offering (the "Offering") of €1,250,000,000 principal amount of 0.000%...

Medtronic Announces Closing of Public Offering of €6.25 Billion of Senior Notes and Redemption of Outstanding Senior Notes

Medtronic Wins Neuromodulation Patent Dispute Against Axonics

DUBLIN, Sept. 25, 2020 /PRNewswire/ -- Medtronic (NYSE:MDT) has won an important victory in a patent dispute over intellectual property for its sacral neuromodulation device family, the InterStim™ systems. The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office...

Medtronic Gets Affirmation of Key Sacral Neuromodulation Patent

DUBLIN, Sept. 24, 2020 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE: MDT) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. ("Medtronic Luxco"), has priced an offering (the "Offering") of €1,250,000,000 principal amount of 0.000% senior notes due...

Medtronic Announces Pricing of €6.25 Billion of Senior Notes

CVS Health

Johnson & Johnson

These companies can serve as a solid foundation for a long-term portfolio.

Top 3 Dividend Stocks You'll Want to Own Forever

This development helps Medtronic (MDT) to augment its research work in the space of interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias.

Medtronic TYRX Driveline Gets FDA's Breakthrough Designation

Abbott Labs

DexCom

Insulet

Here are a few diabetes-centric MedTech stocks that investors can focus on to reap profits amid the pandemic-battered stock market situation.

4 Best Diabetes Device Stocks to Focus on Amid Coronavirus Crisis

American Tower

International Flavors & Fragrances

Sempra Energy

These companies will trade ex-dividend this week. Which, if any, are a buy?

4 Stocks to Consider That Will Trade Ex-Dividend This Week

Medtronic's (MDT) TYRX Envelope lowers infection risks and is cost-effective.

Medtronic's (MDT) TYRX Envelope Study Results Encouraging

The medical device maker is surviving currency fluctuations and seeing strong demand for its ventilators to treat COVID-19 patients.

Medtronic (MDT) Beats Estimates, Holds 200-Day SMA

Morgan Stanley

Medtronic PLC (MDT) CEO Geoff Martha Presents at 2020 Morgan Stanley Global Healthcare Conference (Transcript)

Medtronic (MDT) begins the FDA-approved EFS of Intrepid TTVR system following the receipt of the Breakthrough Device Designation from the regulatory authority.

Medtronic Receives FDA's Go Ahead for EFS Study on TTVR

Investors continue to be optimistic about Medtronic (MDT) on robust segmental growth and strong ventilators sales.

Here's Why You Should Hold on to Medtronic Stock for Now

DUBLIN, Sept. 11, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate virtually in the Morgan Stanley 18th Annual Global Healthcare Conference on Monday, September 14, 2020.

Medtronic CEO Geoff Martha to Speak at Morgan Stanley Global Healthcare Conference

Allscripts Healthcare Solutions

Veeva Systems

In the wake of the pandemic, the remote patient monitoring space continues to thrive on a number of positive developments.

3 Remote Patient Monitoring Stocks in Focus Amid Coronavirus

Medtronic plc (MDT) Management Presents at Wells Fargo Securities 2020 Virtual Healthcare Conference (Transcript)

DUBLIN, Sept. 9, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in structural heart therapies, today announced U.S.

Medtronic Receives Breakthrough Device Designation from FDA, Begins Early Feasibility Study for Investigational Intrepid™ Transcatheter Valve System for the Treatment of Tricuspid Valve Regurgitation

News for Medtronic Stock (MDT)